- Onyx Pharmaceuticals: Inevitable buyout?
- Ipsen: Investing more
- Actelion: New directions
- Regeneron: Shots on goal
- Vertex: Staying aggressive
- Shire: Branching out
- Biogen Idec: Under new management
- Gilead Sciences: Taking its own counsel
- Celgene: The house that Revlimid built
- Amgen: Late-stage focus
- The Biggest R&D Spenders in Biotech
- Tarceva - $564.2 million
- Xeloda - $647.6 million
- Velcade - $692.7 million
- Erbitux - $703.3 million
- Alimta - $1.04 billion
- Eloxatin - $1.2 billion
- Gleevec - $1.51 billion
- Herceptin - $1.66 billion
- Avastin - $2.66 billion
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Chronic Pain Is Relieved by Cell Transplantation in Lab Study
- Drug-vaccine combo better for breast cancer
- Marked for destruction: Newly developed compound triggers cancer cell death
- Orthofix International Completes Divestiture of Sports Medicine Business Unit
- ConforMIS iTotal CR Knee Replacement System Wins Silver in 2012 Medical Design Excellence Awards
- More Press Releases
Featured Jobs
-
Oncology Knowledge Lead
Merck - Boston, MA -
Program Lead - Scientific Information Architecture & Search
Merck - Kenilworth, NJ -
Director, Shared Services Americas Lead Job
Celgene Corporation - Berkeley Heights, NJ, US -
Clinical Trial Manager
TESARO - Waltham, MA -
Senior Manager, Global Market Insights Job
Celgene Corporation - Summit, NJ, US
Latest Commentary